Skip to content

    Cohance Lifesciences Limited

    COHANCEGood
    Healthcare·12 Feb 2025
    Management Summary

    Suven Pharmaceuticals reported a strong recovery in Q3 FY25, characterized by a 40% surge in pro forma combined revenue and a doubling of its Pharma CDMO business. The company is aggressively pivoting towards high-growth niche technologies like ADCs and Oligonucleotides through the acquisitions of NJ Bio and Sapala Organics. While 9M FY25 growth remains modest at 5% due to earlier headwinds in specialty chemicals, management is confident in an accelerated growth trajectory for FY26 and beyond.

    Highlights

    7

    • Pro forma combined revenue grew 40% YoY in Q3 FY25, driven by robust demand across business units.

    • Pharma CDMO segment delivered exceptional growth of 101% YoY on a pro forma combined basis for the quarter.

    • Adjusted EBITDA margin stood at 38.7% for Q3 FY25 and 34.8% for the nine-month period.

    • Phase-3 pipeline expanded to 15 projects with 9 active molecules, up from 12 projects and 7 molecules in the previous quarter.

    • Inbound RFQs increased 2x YoY in the first nine months, reflecting strong innovator confidence.

    • Completed the acquisition of NJ Bio on December 21, 2024, strengthening the ADC (Antibody Drug Conjugate) platform.

    • Management reaffirmed the vision to become a $1 billion revenue company by FY30 with a focus on niche technologies.

    Key financials

    Metrics

    6

    Periods

    2

    Headline

    2
    • Revenue (Pro forma Combined)
      —
      YoY+40%
    • Adjusted EBITDA Margin
      38.7%

    9M

    4
    • Revenue Growth (Pro forma)
      5%
      YoY+5%
    • Adjusted EBITDA Margin
      34.8%
    • CAPEX Investment
      ₹230 Cr
    • Cash Generation
      ₹320 Cr

    Segment breakdown

    Q3 Revenue Growth9M Revenue Growth
    Pharma CDMO101%11%
    API Plus29.0%17%
    Specialty Chemicals CDMO——
    Heatmap· 2 shared metrics

    Guidance & targets

    4
    CategoryTargetPriority
    Revenue
    Total Revenue
    $1 billion
    		High
    Revenue
    Pro forma Combined Revenue Growth
    Positive YoY Growth
    		High
    Revenue
    Revenue Growth Trajectory
    Accelerated
    		Medium
    Capex
    US Facility Expansion
    Commercial facility in New Jersey
    		Medium

    Risks & concerns

    4
    RiskSeverity

    Lumpy nature of CDMO business

    Management repeatedly cautioned that quarter-on-quarter assessments can be counterproductive due to the cyclical nature of the industry. — Management acknowledged

    medium

    Working capital increase

    Suven standalone working capital days increased from 108 to 138 days, attributed to higher sales and new debtors. — Analyst acknowledged

    low

    Specialty Chemicals recovery timing

    While the business has 'bottomed out,' full recovery and accelerated growth are only expected in FY26. — Both acknowledged

    medium

    Areas of Evasion(1)

    • Specific accounting treatment of forward liability impact on future balance sheets was deferred to an offline discussion.

    Q&A highlights

    3

    “At this stage we haven't seen any acceleration in the growth from those two commercial molecules... we expect the demand to come back shortly.”

    Investors are looking for immediate monetization of the late-stage pipeline; management suggests a lag between trial clearance and commercial volume ramp-up.

    asked by Darshit Shah

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Pivot to Niche Technologies

    Suven is aggressively transforming into a technology-led CDMO with a global footprint. The acquisitions of Sapala Organics and NJ Bio have established end-to-end capabilities in high-growth segments like Oligonucleotides and Antibody Drug Conjugates (ADCs). Management highlighted that 40% of the current ADC pipeline uses Camptothecin-based payloads, a segment where Suven holds a competitive advantage in manufacturing key fragments like S-Trione and SN-38.

    02

    Pharma CDMO Pipeline Momentum

    The Pharma CDMO segment was the standout performer in Q3, growing 101% YoY on a pro forma basis. The Phase-3 pipeline has expanded significantly to 15 projects with 9 active molecules, compared to 12 projects and 7 molecules just one quarter ago. This expansion is driven by a strategic focus on 'laterals'—onboarding molecules at later clinical stages—which is expected to fuel commercial growth in FY26 and beyond.

    03

    Specialty Chemicals and API Recovery

    Management indicated that the challenges in the specialty chemicals CDMO business have bottomed out, with early signs of demand stabilization. While this segment faced headwinds earlier in the year, it is being positioned as a dedicated strategic business unit for accelerated growth in FY26. Meanwhile, the API Plus business continues to show resilience, with 29% YoY revenue growth in Q3, supported by a curated portfolio and cost leadership.

    04

    Merger and Integration Progress

    The merger with Cohance Life Sciences is in its final stages, having received 99.99% shareholder approval. The final NCLT meeting is scheduled for February 18, 2025, with the merger expected to be effective within the next 2 to 4 months. Integration efforts are currently focused on front-end synergies and scaling up cGMP facilities to support the newly acquired technology platforms.

    05

    Long-term Financial Aspirations

    Suven has set an ambitious target to reach $1 billion in revenue by FY30. This growth is expected to be driven by a diversified strategy across pharma CDMO, specialty chemicals, and APIs, supplemented by a programmatic M&A approach. The company is also investing in onshore capabilities, including a planned commercial facility in New Jersey, to capture a larger share of the US market for specialized drug development.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.